- Maverix had a busy year in 2021, increasing its exposure to Omolon and doing a meaningful deal with Auramet, which will boost annual GEO sales by more than 12%.
- Meanwhile, the company has seen lots of progress by its operators at both producing royalties and development-stage royalties, with its portfolio getting stronger with no money spent by Maverix.
- Given the company's steady growth and enviable royalty pipeline, I see Maverix as one of the better ways to play the precious metals royalty space.
- So, with the stock pulling back sharply from its highs and being thrown out with the proverbial bathwater, I see this pullback below $4.30 as a low-risk buying opportunity.
For further details see:
Maverix Metals: Low-Risk Exposure To Precious Metals